Diabetic neuropathy represents late diabetes complications, and diabetes duration and long-term hyperglycemia are the main reasons for polyneuropathy. Th e goal was to estimate the eff ects of α-lipoic acid on symptoms of diabetic neuropathy after  mg i.v. for  weeks and  months of - mg of α-lipoic acid per os. Th is study has been designed as a multicentric, in -centers in B&H, carried out by  physicians with  diabetic patients each. Following parameters were monitored in  diabetics suff ering from Type  and Type  diabetes, both men and women: diabetes duration, diabetes therapy, duration of polyneuropathy symptoms, height, weight, BMI (body mass index), subjective assessment of patients, objective examinations of physicians and subjective assessment of physicians.  diabetics, average age ,; oldest , youngest , suff ered from diabetes in average , years. Th ere were  men and  women,  with Type  and  with Type  diabetes, while  patients were not classifi ed.  were having insulin therapy and  oral hypoglicemics. Shortest diabetic status was less than a year, and longest was  years. Average duration of polyneuropathic symptoms was , years, shortest was less than a year, and the longest was  years. Average height was , m, average weight , kg, and average BMI , kg/m. Signifi cant statistic diff erences in improvement were recorded (P>,) according to Fridman' s test for repeated measurements compared to initial fi ndings in assessments: sensory symptoms of polyneuropathy, pain sensations as polyneuropathy symptoms, total score of polyneuropathy symptoms, subjective assessment of patients, subjective fi ndings of physicians, and signifi cant diff erences were not fi nd (P>,) in autonomous and motoric neuropathy. Based on the conducted study, we have concluded that the application of α-lipoic acid during  months has helped to decrease the symptoms of diabetic neuropathy and in only one case out of  included patients there was no subjective improvement after drug application.
Introduction
Diabetic neuropathy represents late micro vascular diabetes complications and it is manifested by slower conduction of nerve impulse and axonal transport damage and nerve cell structure damage. Diabetes duration and long-term hyperglycemia are the main reasons for late diabetes complications and polyneuropathy (,) . Around  of diabetics have already some of polyneuropathy symptoms in the moment when the disease is diagnosed, and according to some epidemiologic researches, - of diabetics have clinical signs of diabetic neuropathy in later phase of the disease. Diff erent symptoms occur depending on place of the changes happening. Dystal sensory and motoric polyneuropathy are most common. Main symptoms are: paresthesia, night pain in muscles, spasms and others (, ) . Th e most common form of diabetic neuropathy is symmetric polyneuropathy and it is manifested through: sensitivity loss on symmetric dystal part of lower limbs, loss of refl exes in feet, balance disorder; paresthesia is manifested through sense of numbness, loss of sense of touch, of pain, "burning sensation" or "tingling" which starts in feet and then spreads up to upper part of legs. Neuropathic pain usually aff ects lower limbs, present when resting and increases at night. Diabetic neuropathy is divided into: a) Dystal polyneuropathy (sensory-motoric, mostly sensory and mostly motoric), b) Proximal polyneuropathy, c) Autonomous neuropathy (loss of hypoglycemia warning signs, change in pupilary function of function of lachrymal gland, cardiovascular and lung disturbances, thermoregulatory disturbances, gastrointestinal disturbances, genitourinary disturbances). In order to set up diagnosis, beside history data and clinical picture, one must also undergo electromyography (EMG) of limbs which shows the speed of nerves conduction (,,) .
Materials and Methods
This study has been designed as a multicentric, in -centers in B&H, carried out by  physicians with  diabetic patients each. Following parameters were monitored in  diabetics suff ering from Type  and Type  diabetes, both men and women: diabetes duration, diabetes therapy, duration of polyneuropathy symptoms, heights, weight, BMI (body mass index). Following symptoms of polyneuropathy were monitored: autonomous, sensory, motoric, pain sensation, total sum of symptoms All above said symptoms have been graded at the beginning of the research:
No symptoms -; Mild -; Moderate -; Severe -; Total sum of all symptoms During the follow-ups, once in  days, patients subjectively assessed their condition as: Worsening -;Unchanged -; Moderate improvement -; Signifi cant improvement - During the follow-ups, once in  days, based in subjective assessment of symptoms and objective examinations, the physicians assessed the condition as: Worsening -; Unchanged -; Moderate improvement -; Signifi cant improvement - Administering protocol was same for all patients:  weeks, from Monday to Friday, they received  mg i.v. of α-lipoic acid and during the weekend they took x tablets of  mg. In next  months, the patients took x or x tablets of  mg.
Results
 diabetics, average age , years, oldest , youngest , suffered from diabetes in average , years. Th ere were  men and  women,  with Type  and  with Type  diabetes, while  patients were not classifi ed.  were having insulin therapy and  oral hypoglicemics. Shortest diabetic status was less than a year, and longest was  years. Average duration of polyneuropathic symptoms was , years, shortest was less than a year, and the longest was  years. Average height was , m, average weight , kg, and average BMI , kg/m. Table . shows the symptoms of autonomous polyneuropathy at the beginning of the research and during  follow-ups, done in descriptive manner.
According to Fridman's test for repeated measurements there were no signifi cant statistic diff erences in initial fi ndings, follow-ups and last fi nding of changes with respect to signs of autonomous polyneuropathy. Table  . shows the symptoms of sensory polyneuropathy at the beginning of the research and during  follow-ups, done in descriptive manner.
According to Fridman's test for repeated measurements there were signifi cant statistic diff erences in initial fi ndings, follow-ups and last fi nding of changes, where p<, since the fourth follow-up with respect to signs of sensory polyneuropathy. Table . shows the symptoms of motoric polyneuropathy at the beginning of the research and during  follow-ups, done in descriptive manner. According to Fridman's test for repeated measurements there were no signifi cant statistic diff erences in initial fi ndings, follow-ups and last fi nding of changes with respect to signs of motoric polyneuropathy. Table . shows the symptoms of pain sensation as a sign of polyneuropathy at the beginning of the research and during  follow-ups, done in descriptive manner.
According to Fridman's test for repeated measurements there were significant statistic differences in initial fi ndings, follow-ups and last fi nding of changes, where p<, since the fourth follow-up with respect to pain sensation as a symptom of polyneuropathy. Table . shows the sum findings polyneuropathy signs (autonomous, sensory, motoric and pain sensation) at the beginning of the research and during  follow-ups, done in descriptive manner. According to Fridman's test for repeated measurements there were significant statistic differences in initial findings, follow-ups and last finding of changes, where p<, since the fourth follow-up when all symptoms of polyneuropathy have been summed up. Table  . shows the subjective assessment of patients on severity of polyneuropathy signs (autonomous, sensory, motoric and pain sensation) at the beginning of the research and during  follow-ups, done in descriptive manner.
According to Fridman's test for repeated measurements there were significant statistic differences in initial fi ndings, follow-ups and last fi nding of changes, where p<, since the third follow-up when patients expressed on changes in symptoms of polyneuropathy. Table  . shows the assessment of physicians on severity of polyneuropathy signs (autonomous, sensory, motoric and pain sensation) based on the objective examination and subjective assessments at the beginning of the research and during  follow-ups, done in descriptive manner. According to Fridman's test for repeated measurements there were significant statistic differences in initial fi ndings, follow-ups and last fi nding of changes, where p<, since the second follow-up when physicians expressed the changes in symptoms of polyneuropathy.
Discussion
Diabetic neuropathy represents late micro vascular diabetes complications and it is manifested by slower conduction of nerve impulse and axonal transport damage and nerve cell structure damage. Diabetes duration and long-term hyperglycemia are the main reasons for late diabetes complications and polyneuropathy. Polyneuropathy and its symptoms are very uncomfortable for patients and can lead to severe disability, which represents huge medical, social and economic problem (,) . Consequences of late diabetes complications are much harder to treat than diabetes itself. Th is refers to polyneuropathy as well. Products of α-lipoic acid are used lately to treat diabetic polyneuropathy. Studies done throughout the world showed the success of α-lipoic acid () . ALADIN I study was designed so to show the effects of α-lipoic acid after short term ap- 
Conclusion
Based on our research, we came to the following conclusions: . Th ere were signifi cant statistic diff erences (P<,) compared to initial fi ndings when assessed: sensory polyneuropathy symptoms; pain sensations as polyneuropathy symptoms; total score of polyneuropathy symptoms;subjective assessments of patients; subjective fi ndings of physicians . Th ere were no diff erences (P>,) between the initial fi ndings and fi nal fi nding in autonomous polyneuropathy symptoms and motoric polyneuropathy symptoms, although certain improvements were recorded also in these assessments. A possible reason for such result is a lack of polyneuropathy symptoms in this group of patients referring to autonomous and motoric symptoms and in that case we cannot expect improvements in that sense. . Based on our research, we have concluded that the application of α-lipoic acid during  months has helped to decrease the symptoms of diabetic polyneuropathy and that in only one case out of  included patients there was no subjective improvement after drug application.
